Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

IOL Chemicals and Pharmaceuticals Limited

NSE: IOLCPPharmaceuticalsASM stage 1

Share price

₹205.55

-6.66% close of 8 Oct 2026

Market cap ₹6,064 CrP/E 34.5

Business score

How strong the business is, in one number. The parts behind it are in Pro.

54

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹6,064 Cr

P/E ratio

34.5

P/B ratio

3.4

ROCE

11.3%

ROE

8.4%

Dividend yield

0.5%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹220.2252-week low ₹68.21

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 18.6% over the past year, and 15.0% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 9.1% to 12.1% over the last four years.

Whether it grew faster than its sector

It grew 15.0% a year against a sector median of 13.1% — 1.9 percentage points faster.

Room to re-rate, or risk of de-rating

At 34.5× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 18.6×, the 99th percentile of its own range.

Whether growth justifies the valuation

Priced at 17.2 times its growth rate, on earnings growth of 2%.

Profit growthPrice per ₹1 profitPer 1% growth
IOL Chemicals and Pharmaceuticals Limited — this one2%/yr34.5×₹17.2
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 84 of 130 on returns, 41 of 127 on growth, 91 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 11.3% on capital, ahead of 35% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years it made ₹898 crore of cash from the business but spent ₹1017 crore on plant and equipment, ₹119 crore more than it made, paid from its own cash and investments. And the profit is real: of every 100 rupees it reported over 5 years, about 132 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back faster than it used to: it went from being waiting 71 days for its cash to waiting 53 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue rose 37% and profit rose 89%, while full-year growth targets were left broadly unchanged.

Announced 10 Aug 2026 · Consolidated · Unaudited

Revenue

₹756 Cr

Revenue vs last year

+37.0%

Revenue vs last quarter

+22.2%

Net profit

₹64 Cr

Profit vs last year

+89.4%

Profit vs last quarter

+21.5%

Net margin

8.5%

EPS

₹2.20

Earnings call transcript · 13 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹6,064 Cr
Prev close
₹205.55
52w High
₹224
52w Low
₹67.2
Enterprise value
₹5,997 Cr
Beta
1.4
Price CAGR 1y
114.0%
Price CAGR 3y
34.0%
Price CAGR 5y
13.0%
Price CAGR 10y
23.0%

Ratios

Return on assets
5.3%
PEG ratio
17.1
P/E ratio
34.5
P/B ratio
3.4
EV / EBITDA
19.4
Industry P/E
38.0
ROCE
11.3%
ROCE 5y average
11.5%
ROE
8.4%
Debt / Equity
0.1
Interest coverage
13.3
Dividend yield
0.5%
ROE 3y average
8.0%
ROE last year
8.0%

Annual P&L

Annual revenue
₹2,319 Cr
Annual profit
₹138 Cr
Operating margin
12.0%
Net profit margin
6.0%
EBITDA margin
11.6%
Sales growth 3y
1.5%
Sales growth 5y
—
Profit growth 3y
2.0%
Profit growth 5y
—
EPS
₹4.7
Sales growth TTM
19.0%
Profit growth TTM
68.0%
Dividend payout
21.0%

Quarter P&L

Sales latest quarter
₹756 Cr
Profit latest quarter
₹64 Cr
YoY quarterly sales growth
37.1%
YoY quarterly profit growth
88.2%
OPM latest quarter
13.7%

Balance Sheet

Book Value
₹61.0
Face Value
₹2.0
Total debt
₹135 Cr
Total cash
₹198 Cr
Borrowings
₹135 Cr
Reserves / Equity
29.5

Cash Flow

Operating cash flow
₹214 Cr
Free cash flow
₹43 Cr
FCF yield
0.5%
Net cash flow
-₹13 Cr

Shareholding

Promoter holding
62.3%
FII holding
4.9%
DII holding
0.4%
Public holding
32.4%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
IOL Chemicals220.2236.66,4640.4564.489.8756.337.111.3
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales563545520504502526523528552568580619756
Expenses491481476454451484476465490510523527653
Material Cost348377367357402507
Change in Inventories-1.82-121.4726-33-30
Purchases of Stock-in-Trade0000.193.830.75
Employee Cost525863577071
Other Expenses6768798484104
Operating Profit736444505142476362575792103
OPM %13128.529.83107.918.961211109.871514
Other Income7788764577-628
Exceptional items (within Other Income)000-1100
Interest4443244443434
Depreciation14161616171819192020202021
Profit before tax61513237402628454640287187
Tax %25262826242626302526252526
Net Profit46382328301921313430215364
EPS in Rs1.561.290.790.941.020.650.701.071.161.020.701.812.19
Diluted EPS in Rs1.071.161.020.701.812.20

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,1842,2172,1332,0792,3192,524
Expenses1,9251,9911,9021,8772,0492,213
Material Cost1,3581,502
Change in Inventories34-19
Purchases of Stock-in-Trade04.02
Employee Cost217248
Other Expenses268315
Operating Profit259226231202270310
OPM %121011101212
Other Income17253022911
Exceptional items (within Other Income)0-11
Interest81616151514
Depreciation434663728082
Profit before tax225189182138184226
Tax %2526262725
Net Profit168139134101138168
EPS in Rs5.714.744.583.444.695.72
Diluted EPS in Rs3.444.69
Dividend Payout %1417222321

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
—
3 years
2%
TTM
19%

Compounded profit growth

10 years
—
5 years
—
3 years
2%
TTM
68%

Stock price CAGR

10 years
23%
5 years
13%
3 years
34%
1 year
114%

Return on equity

10 years
—
5 years
9%
3 years
8%
Last year
8%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital5959595959
Reserves1,3341,4491,5531,6291,740
Borrowings448033117135
Other Liabilities526435600577653
Total Liabilities1,9622,0222,2442,3822,587
Fixed Assets5617529331,1711,182
CWIP105901012296
Investments220202121
Other Assets1,2941,1611,1901,1691,289
Total Assets1,9622,0222,2442,3822,587

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity93122290179214
Cash from Investing Activity-121-120-191-154-198
Cash from Financing Activity-2-4-9246-29
Net Cash Flow-29-2670-13
Free Cash Flow-58-8717-3443

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days7983819095
Inventory Days95771119591
Days Payable9574123112118
Cash Conversion Cycle7986697368
Working Capital Days7172715853
ROCE %1412911

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters484848484853535353535762
FIIs2.332.181.401.391.631.491.472.592.252.081.724.87
DIIs0.350.360.290.090.070.080.070.020.050.030.020.43
Public494950505046464545454132
No. of Shareholders1,35,3971,34,2351,30,0031,28,6891,25,9791,26,7011,30,0021,25,0401,36,1291,33,5311,31,5501,19,311

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +105.3% (₹100.13 → ₹205.55)Brick size ₹11.37 (fixed)Bricks 17
₹100₹150₹206Jan '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹205.55 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

exports as % of revenue

28.50pct

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-66.51inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

74,92,924inr

2026-03-31

News

News and filings about IOL Chemicals and Pharmaceuticals Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Acetic Acid
  • Aluminium Chloride
  • Dicyandiamide
  • Iso Butyl Benzene (IBB) intermediate for ibuprofen
  • Propylene
  • Sodium Di Chromate
  • Sodium Metal
  • Specially Denatured Spirit (industrial ethanol)
  • Toluene

Depends on the price of

  • propylene

Sells to

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE485C01029

Business segments

  • Pharmaceutical · 55%
  • Chemical · 45%

Plants

  • API Unit-1 · Barnala, Punjab
  • API Unit-2 · Barnala, Punjab
  • Acetic Anhydride Unit · Barnala, Punjab
  • Acetyl Chloride Unit · Barnala, Punjab
  • Ethyl Acetate Unit · Barnala, Punjab
  • Integrated manufacturing facility, Village Fatehgarh Channa, Mansa Road · Barnala, Punjab
  • Iso Butyl Benzene Unit · Barnala, Punjab
  • Mono Chloro Acetic Acid Unit · Barnala, Punjab
  • Paracetamol Unit-11 · Barnala, Punjab

News impact

Big market events that reach IOL Chemicals and Pharmaceuticals Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

17 Feb 2026interim₹1
11 Mar 2025split₹0
18 Feb 2025interim₹4
16 Feb 2024interim₹5
17 Feb 2023interim₹4
15 Feb 2022interim₹4
8 Sep 2021unspecified₹2
17 Nov 2020interim₹4

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
8 Jul 2026HRTI PRIVATE LIMITEDSELL21,61,991₹169.61
8 Jul 2026MICROCURVES TRADING PRIVATE LIMITEDSELL15,74,122₹171.04
8 Jul 2026MICROCURVES TRADING PRIVATE LIMITEDBUY15,74,122₹170.97
8 Jul 2026QE SECURITIES LLPBUY15,49,954₹168.77
8 Jul 2026QE SECURITIES LLPSELL15,15,110₹170.49
8 Jul 2026HRTI PRIVATE LIMITEDBUY11,47,860₹168.72
7 Jul 2026POLUNIN EMERGING MARKETS SMALL CAP FUND LLCBUY44,19,222₹166.65

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.